Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Location [1]
Chromatin remodeling/DNA methylation, Metabolic signaling
Protein [2]
Isocitrate dehydrogenase [NADP] cytoplasmic
Synonyms [1]

IDH1 (isocitrate dehydrogenase 1 (NADP+), soluble) encodes for the isocitrate dehydrogenase [NADP] cytoplasmic protein, an epigenetic modifier. IDH1 is frequently mutated in glioma and acute myeloid leukemia, among other cancer types (PMID: 23558169).


IDH1 is altered in 2.85% of all cancers with anaplastic astrocytoma, oligodendroglioma, astrocytoma, conventional glioblastoma multiforme, and anaplastic oligodendroglioma having the greatest prevalence of alterations [3].

IDH1 GENIE Cases - Top Diseases

The most common alterations in IDH1 are IDH1 Mutation (2.75%), IDH1 Codon 132 Missense (2.29%), IDH1 R132H (1.45%), IDH1 R132C (0.62%), and IDH1 R132G (0.12%) [3].

IDH1 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of IDH1 in Diseases

Acute Myeloid Leukemia +

Cholangiocarcinoma +

Chondrosarcoma +

Malignant Solid Tumor +

Glioma +

Myelodysplastic Syndromes +

Malignant Glioma +

WHO Grade II Glioma +

Anaplastic Astrocytoma +

Oligodendroglioma +

Astrocytoma +

Myeloproliferative Neoplasm +

Lymphoma +

Breast Carcinoma +

Diffuse Astrocytoma +

WHO Grade III Glioma +

Glioblastoma +

Hematopoietic And Lymphoid Malignancy +

Myelodysplastic Syndrome With Excess Blasts-2 +

Chronic Myelomonocytic Leukemia +

Non-Small Cell Lung Carcinoma +

Pancreatic Carcinoma +

Ovarian Carcinoma +

Ependymoma +

Mixed Glioma +

Anaplastic Oligodendroglioma +

Oligoastrocytoma +

Low Grade Glioma +

Diffuse Glioma +

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative +

Intrahepatic Cholangiocarcinoma +

High-Grade Glioma, NOS +

Bile Duct Carcinoma +

Malignant Hepatobiliary Neoplasm +

Secondary Acute Myeloid Leukemia +

Therapy-Related Acute Myeloid Leukemia +

Myeloproliferative Neoplasm, Unclassifiable +

Leukemia +

Myeloid Neoplasm +

Melanoma +

Cancer +

Acute Promyelocytic Leukemia +

Medulloblastoma +

Central Nervous System Embryonal Neoplasm +

Diffuse Midline Glioma, H3 K27M-Mutant +

Essential Thrombocythemia +

Primary Brain Neoplasm +

Myelofibrosis Transformation In Essential Thrombocythemia +

Primary Myelofibrosis +

Chronic Myeloid Leukemia +

Myelofibrosis +

Schwannoma +

Bladder Carcinoma +

Colorectal Carcinoma +

Sarcoma +

Gallbladder Carcinoma +

Myelodysplastic/Myeloproliferative Neoplasm +

Prostate Carcinoma +

Head And Neck Carcinoma +

Hepatocellular Carcinoma +

Gastric Carcinoma +

Multiple Myeloma +

Gastrointestinal Stromal Tumor +

Pleural Mesothelioma +

Renal Cell Carcinoma +

Clear Cell Renal Cell Carcinoma +

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +

Anaplastic Astrocytoma, IDH-Mutant +

Anaplastic Ependymoma +

Anaplastic Oligodendroglioma, IDH-Mutant And 1p/19q-Codeleted +

Anaplastic Pleomorphic Xanthoastrocytoma +

Atypical Teratoid/Rhabdoid Tumor +

Central Nervous System Ganglioneuroblastoma +

Central Nervous System Neuroblastoma +

Embryonal Tumor With Multilayered Rosettes, C19MC-Altered +

Embryonal Tumor With Multilayered Rosettes, Not Otherwise Specified +

Ependymoma, RELA Fusion-Positive +

Histiocytosis +

Medulloblastoma, Non-WNT/Non-SHH +

Medulloblastoma, SHH-Activated +

Medulloblastoma, WNT-Activated +

Medulloepithelioma +

Meningioma +

Papillary Renal Cell Carcinoma +

Peritoneal Mesothelioma +

Plasma Cell Leukemia +

Polycythemia Vera +

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase +

Primary Central Nervous System Lymphoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.